<PAGE> UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Name of Issuer: IDEC Pharmaceuticals Corporation Title of Class of Securities: Common Stock CUSIP Number: 449370105 (Name, Address and Telephone Number of Person Authorized To Receive Notices and Communications) Norman S. Schleifer c/o Oracle Partners, L.P. 712 Fifth Avenue, 45th Floor New York, New York 10019 (Date of Event which Requires Filing of this Statement) March 5, 1997 If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ]. Check the following line if a fee is being paid with this statement. (A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of class. See Rule 13d-7). *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
<PAGE> CUSIP No.: 449370105 1. Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person Larry N. Feinberg, SS#: 009-42-3868 2. Check the Appropriate Box if a Member of a Group a. b. 3. SEC Use Only 4. Source of Funds WC 5. Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e) 6. Citizenship or Place of Organization United States Number of Shares Beneficially Owned by Each Reporting Person With: 7. Sole Voting Power: 988,600 8. Shared Voting Power: 9. Sole Dispositive Power: 988,600 10. Shared Dispositive Power: 11. Aggregate Amount Beneficially Owned by Each Reporting Person 988,600 12. Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares 2
<PAGE> 13. Percent of Class Represented by Amount in Row (11) 5.47% 14. Type of Reporting Person IN *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION. 3
<PAGE> Item 1. Security and Issuer This statement relates to shares of common stock (the "Common Stock") of IDEC Pharmaceuticals Corporation ("IDEC"). IDEC's principal executive office is located at 11011 Torreyana Road, San Diego, CA 92121. Item 2. Identity and Background This statement is being filed on behalf of Mr. Larry N. Feinberg. Mr. Feinberg is the managing general partner of Oracle Partners, L.P. and Oracle Institutional Partners, L.P., both of which are investment limited partnerships (the "Partnerships"), and has investment discretion over certain managed accounts. The principal offices of the Partnerships are at 712 Fifth Avenue, 45th Floor, New York, New York 10019. Mr. Feinberg has not during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). Mr. Feinberg has not during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws. Mr. Feinberg is a citizen of the United States of America. 4
<PAGE> Item 3. Source and Amount of Funds or Other Consideration As of the date hereof, Mr. Feinberg is deemed to beneficially own 988,600 shares of IDEC's Common Stock (the "Shares"). The Shares are held by the Partnerships and by managed accounts over which Mr. Feinberg has investment discretion. The 988,600 Shares were purchased in open market transactions at an aggregate cost of $19,063,609. The funds for the purchase of the Shares held in the Partnerships, over which Mr. Feinberg has investment discretion, came from capital contributions to the Partnerships by their general and limited partners. The funds for the purchase of the Shares held in the managed accounts, over which Mr. Feinberg has investment discretion, came from each managed account's own funds. No leverage was used to purchase the Shares.
Item 4. Purpose of Transaction The Shares deemed to be beneficially owned by Mr. Feinberg were acquired for, and are being held for, investment purposes. Mr. Feinberg may acquire additional shares of Common Stock, dispose of all or some of the Shares from time to time, in each case in open market transactions, block sales or purchases or otherwise, or may continue to hold the Shares. Mr. Feinberg does not have any plan or proposal which relates to, or would result in, any of the actions 5
<PAGE> enumerated in Item 4 of the instructions to Schedule 13D. However, Mr. Feinberg reserves the right to discuss company business with management, make proposals to management and/or take other actions to influence the management of Murex should he deem such actions appropriate.
Item 5. Interest in Securities of the Issuer As of the date hereof, Mr. Feinberg is deemed to be the beneficial owner of 988,600 shares of IDEC's Common Stock. Based on information received from the management of IDEC, there are believed to be 18,059,258 shares of IDEC's Common Stock outstanding. Therefore, Mr. Feinberg is deemed to beneficially own 5.47% of IDEC's outstanding shares of Common Stock. Mr. Feinberg has the power to vote, direct the vote, dispose of or direct the disposition of all the shares of IDEC's Common Stock that he is currently deemed to beneficially own. Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer Mr. Feinberg does not have any contract, arrangement, understanding or relationship with any person with respect to the Common Stock of IDEC. Item 7. Material to be Filed as Exhibits Attached hereto as Exhibit A is a description of the transactions in the Common Stock of IDEC that were effected by Mr. Feinberg during the past 60 days. 6
<PAGE> Signature The undersigned, after reasonable inquiry and to the best of his knowledge and belief, certifies that the information set forth in this statement is true, complete and correct. March 10, 1997 /s/ Larry N. Feinberg ________________________________ Larry N. Feinberg 00751001.AQ1 7
<PAGE> EXHIBIT A Daily Transactions Common Stock Trade Date Number of Shares Price Per Share Value 01/28/97 50,000 $22.0625 $1,103.125 01/29/97 25,000 21.6250 540,625 01/31/97 5,000 22.5000 112,500 01/31/97 12,500 22.5000 281,250 02/05/97 50,000 22.6875 1,134,375 02/11/97 15,000 20.8750 313,125 02/12/97 35,000 21.5536 754,376 02/13/97 15,000 22.5000 337,500 02/18/97 20,000 22.5000 450,000 02/20/97 50,000 23.4000 1,170,000 02/24/97 25,000 23.7500 593,750 02/25/97 20,000 24.4375 488,750 02/26/97 10,000 23.8125 238,125 02/28/97 30,000 24.8333 744,999 03/04/97 75,000 24.7083 1,853,123 03/05/97 25,000 24.7500 618,750 8 00751001.AQ1